Lack of Cross-Reactivity Allergy Following a Switch from Alirocumab to Evolocumab
Loading...
Issue Date
2016
Authors
Stryker, Matthew D.
Kane, Michael P.
Busch, Robert
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene and gain-of-function mutations were first described in 2003. The gain-of-function mutations observed were associated with low-density lipoprotein-cholesterol (LDL-C) levels in the 400’s, in addition to premature cardiovascular disease. Subsequent loss-of-function experiments conducted in mice demonstrated marked reductions in plasma cholesterol levels in the absence of PCSK9. Physiologically, PCSK9 serves as a chaperone protein and functions to reduce low-density lipoprotein (LDL) receptor recycling; consequently, less LDL-C is removed from circulation and serum lipid concentrations become elevated. Inhibition of PCSK9 prevents LDL receptor degradation and preserves receptor recycling to the hepatocyte surface; this in turn results in reduced LDL-C levels. We report a lack of cross-sensitivity following the administration of evolocumab after an allergic reaction to alirocumab.
Citation
Stryker, Matthew D., et al. “Lack of Cross-Reactivity Allergy Following a Switch from Alirocumab to Evolocumab.” Excerpts in Pharmacy Research Journal, vol. 2, no. 1, 2016, https://digitalcommons.cedarville.edu/excerpts_in_pharmacy_research_journal/vol2/iss1/3/.
ACPHS Research Commons URI
Description
Click on the Resource Link to access the article (may not be free).